KR20220008893A - 피부 홍반성 루푸스의 치료 - Google Patents

피부 홍반성 루푸스의 치료 Download PDF

Info

Publication number
KR20220008893A
KR20220008893A KR1020217041029A KR20217041029A KR20220008893A KR 20220008893 A KR20220008893 A KR 20220008893A KR 1020217041029 A KR1020217041029 A KR 1020217041029A KR 20217041029 A KR20217041029 A KR 20217041029A KR 20220008893 A KR20220008893 A KR 20220008893A
Authority
KR
South Korea
Prior art keywords
compound
present
formula
lupus erythematosus
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217041029A
Other languages
English (en)
Korean (ko)
Inventor
야코브 닐센
기테 포메르고르 페데르센
헬레네 모르텐센
카밀라 산데르
피아 클리 레페르
Original Assignee
레오 파마 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레오 파마 에이/에스 filed Critical 레오 파마 에이/에스
Publication of KR20220008893A publication Critical patent/KR20220008893A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217041029A 2019-05-15 2020-05-14 피부 홍반성 루푸스의 치료 Ceased KR20220008893A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19174586 2019-05-15
EP19174586.8 2019-05-15
PCT/EP2020/063518 WO2020229622A1 (en) 2019-05-15 2020-05-14 Treatment of cutaneous lupus erythematosus

Publications (1)

Publication Number Publication Date
KR20220008893A true KR20220008893A (ko) 2022-01-21

Family

ID=66554234

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217041029A Ceased KR20220008893A (ko) 2019-05-15 2020-05-14 피부 홍반성 루푸스의 치료

Country Status (15)

Country Link
US (2) US20220241284A1 (https=)
EP (1) EP3968997B1 (https=)
JP (2) JP7734587B2 (https=)
KR (1) KR20220008893A (https=)
CN (1) CN113825512A (https=)
AU (1) AU2020275208B2 (https=)
BR (1) BR112021022031A2 (https=)
CA (1) CA3137247A1 (https=)
IL (1) IL288011A (https=)
MX (1) MX2021012874A (https=)
SG (1) SG11202110777XA (https=)
TW (1) TWI863995B (https=)
UA (1) UA129431C2 (https=)
WO (1) WO2020229622A1 (https=)
ZA (1) ZA202107300B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023202989A1 (en) 2022-04-20 2023-10-26 Leo Pharma A/S Treatment of frontal fibrosing alopecia
WO2024194105A1 (en) * 2023-03-17 2024-09-26 Leo Pharma A/S A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema
WO2025085050A1 (en) * 2023-10-16 2025-04-24 Leo Pharma A/S Treatment of frontal fibrosing alopecia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1697342A2 (en) * 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8883838B2 (en) * 2010-12-03 2014-11-11 Allergan, Inc. Pharmaceutical cream compositions and methods of use
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2016112208A2 (en) * 2015-01-09 2016-07-14 Kineta One, Llp Topical applications of kv1.3 channel blocking peptides to treat skin inflammation
PT3297605T (pt) * 2015-05-21 2022-05-30 Dermavant Sciences GmbH Composições farmacêuticas tópicas
DK3405197T3 (da) * 2016-01-21 2023-11-27 Leo Pharma As Topisk behandling af håndeksem

Also Published As

Publication number Publication date
AU2020275208A1 (en) 2021-10-28
UA129431C2 (uk) 2025-04-23
JP2025114800A (ja) 2025-08-05
CN113825512A (zh) 2021-12-21
EP3968997B1 (en) 2026-03-18
EP3968997A1 (en) 2022-03-23
BR112021022031A2 (pt) 2021-12-28
AU2020275208B2 (en) 2025-12-04
US20260069595A1 (en) 2026-03-12
TWI863995B (zh) 2024-12-01
WO2020229622A1 (en) 2020-11-19
CA3137247A1 (en) 2020-11-19
TW202106690A (zh) 2021-02-16
JP7734587B2 (ja) 2025-09-05
JP2022533526A (ja) 2022-07-25
SG11202110777XA (en) 2021-11-29
MX2021012874A (es) 2021-11-17
US20220241284A1 (en) 2022-08-04
IL288011A (en) 2022-01-01
ZA202107300B (en) 2025-12-17

Similar Documents

Publication Publication Date Title
AU2022252766B2 (en) Treatment of hand eczema
US20260069595A1 (en) Formulation of delgocitinib in the form of a cream
KR101951220B1 (ko) 조합 als 치료법
WO2023202989A1 (en) Treatment of frontal fibrosing alopecia
RU2847397C2 (ru) Лечение кожной формы красной волчанки
HK40063225A (en) Treatment of cutaneous lupus erythematosus
HK40102338A (en) Treatment of hand eczema
HK1260652B (en) Use of delgocitinib for the treatment of chronic hand eczema
HK1260652A1 (en) Use of delgocitinib for the treatment of chronic hand eczema

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601